New Cancer Drug Combination for Advanced Lung Tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a new two-drug combination (risvutatug rezetecan and ivonescimab) to treat advanced lung cancers that have spread. The drugs work by targeting cancer cells in a new way and may help people whose cancers have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced or metastatic lung cancer (small-cell or non-small-cell) confirmed by biopsy
- Your cancer has at least one measurable tumor on imaging
- You are well enough to tolerate treatment (ECOG score 0–1, meaning you can do light daily activities)
- You have tumor tissue available (recent or archived biopsy samples) for testing
- Your heart, kidneys, liver, and blood counts are working well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (ivonescimab with either dato-DXd or osimertinib) for people with advanced lung cancer that has a specific EGFR gene mutation and has already been treated with other therapies. The goal is to see if this combination can help control the cancer better than current options.
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
This study tests a combination of two experimental drugs (EVM14 and ivonescimab) in patients with advanced squamous cell lung cancer that cannot be cured with surgery or radiation alone. The drugs work by helping your immune system fight cancer cells.
This study tests a new drug (rilvegostomig) alone or with chemotherapy or another drug (ramucirumab) for advanced non-small cell lung cancer that has spread. It aims to see if these combinations work better than standard treatments.
This study tests a combination of two newer drugs (trastuzumab rezetecan and ivonescimab) for advanced non-small cell lung cancer whose cancer cells have a specific HER2 gene change. The trial includes two groups: people who have already tried one round of treatment, and people newly diagnosed who haven't had treatment yet.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.